Market-Moving News for May 10th
$ITOS
$LIDR
$NVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Auto Parts:O.E.M.
Consumer Discretionary
Get the next $ITOS alert in real time by email
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/24/2025 | $18.00 | Overweight | Cantor Fitzgerald | |
| 9/8/2025 | $6.00 | Buy | Alliance Global Partners | |
| 8/28/2025 | $10.00 | Buy | H.C. Wainwright | |
| 8/20/2025 | $7.00 | Neutral → Underperform | BofA Securities | |
| 6/17/2025 | $6.00 | Sell | Citigroup | |
| 5/28/2025 | $12.00 | Overweight → Equal Weight | Wells Fargo | |
| 5/28/2025 | $12.00 | Outperform → Neutral | Wedbush | |
| 5/14/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
4 - AEye, Inc. (0001818644) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - AEye, Inc. (0001818644) (Issuer)
Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its productsProvides Novavax with an upfront payment of $30 million with the potential for up to another $500 million in development and sales milestones. In addition to milestone payments, Novavax is eligible to receive high mid-single digit percentage royaltiesGAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of the agreement, Pfizer will obtain a non-exclusive license for Matrix-M for use with Pfizer's products in up to two disease areas. "The Novavax
AEye, Inc. (NASDAQ:LIDR), a global leader in software-defined, high-performance lidar solutions, today announced a strategic partnership with Vueron, to incorporate Vueron's real-time 3D perception software into the OPTIS™ ecosystem. AEye is continuing to expand the reach of OPTIS™ by delivering on its commitment to create a full-stack 3D visual awareness system that delivers real-time detection and analysis across critical use cases in automotive, infrastructure, transportation, and safety applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114450767/en/AEye CEO Matt Fisch and Vueron CEO Joseph Kim sign partnership
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation Date: Wednesday, January 14, 2026 Time: 4:30 p.m. Pacific Time Location: San Francisco, CA A webcast of the presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven techn
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - AEye, Inc. (0001818644) (Issuer)
SCHEDULE 13G - NOVAVAX INC (0001000694) (Subject)
SCHEDULE 13G - AEye, Inc. (0001818644) (Subject)
8-K - NOVAVAX INC (0001000694) (Filer)
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of
For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO
Cantor Fitzgerald resumed coverage of Novavax with a rating of Overweight and set a new price target of $18.00
Alliance Global Partners initiated coverage of AEye with a rating of Buy and set a new price target of $6.00
H.C. Wainwright resumed coverage of Novavax with a rating of Buy and set a new price target of $10.00
Doubled customer base, fueling expansion across high-growth markets Secured strategic investment to significantly expand Apollo production capacity AEye, Inc. (NASDAQ:LIDR), a global leader in software-defined lidar solutions, and the manufacturer of the Apollo lidar sensor, today announced its results for the third quarter ended September 30, 2025. Recent Business Highlights Captured six new business wins since end of Q2, with 12 customer contracts signed year-to-date Secured strategic investment with leading global investor to expand Tier-1 manufacturing partnership and scale Apollo production to 60,000 units annually Delivered Apollo units to a global defense contractor powering
Total revenue of $70 million in the third quarter of 2025Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on marketing authorization transfersSanofi reported preliminary positive immunogenicity and safety Phase 1/2 data for Nuvaxovid™ in combination with both Fluzone High-Dose and FlublokSanofi received BARDA grant for pandemic influenza vaccine candidate using Novavax's Matrix-M® adjuvantMaryland site consolidation transactions resulted in $60 million cash proceeds and approximately $230 million in expected future cost savingsRaises Full Year 2025 Revenue Framework and Affirms Financial GuidanceCompany to
GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of the event and replay are as follows: Conference call details: Date: November 6, 2025 Time: 8:30 a.m. ET URL to register phone: Register Here Dial-in number: (888) 880-3330 (U.S.) or (+1) (646) 357-8766 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering thei
AEye, Inc. (NASDAQ:LIDR), a global leader in adaptive, high-performance lidar solutions, announced it has appointed Doron Simon to its Board of Directors effective April 29, 2025. Mr. Simon's appointment is the result of the Company's commitment to the thoughtful and continuous refreshment of its Board to best meet the evolving needs of AEye. Mr. Simon, age 59, brings deep experience in strategic consulting and M&A advisory services as the Founder of DSimonSays Inc., Managing Director at Stanton Park Capital, and a Partner at Transformation Equity Partners. His advisory work focuses on scaling technology firms to profitability through organic and non-organic growth. Prior to being an advis
GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp
Reaffirms the Company's Focus on Driving Long-Term Value Creation Urges Stockholders to Vote Only with the WHITE Proxy Card "FOR" ALL Company Proposals, Including AEye's Highly Qualified Director Nominees, and "AGAINST" ALL Shareholder Proposals AEye, Inc. (NASDAQ:LIDR), a global leader in adaptive, high-performance lidar solutions, sent a letter to stockholders today highlighting key information to support informed voting at its upcoming annual meeting on May 15, 2025. Stockholders of record as of April 4, 2025 are entitled to vote at this year's meeting. AEye urges stockholders to protect their investment and the future of the Company by voting only on the WHITE proxy card "FOR" AEye's
SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)